{
    "Trade/Device Name(s)": [
        "AESKULISA PR3"
    ],
    "Submitter Information": "AESKU.DIAGNOSTICS",
    "510(k) Number": "K091859",
    "Predicate Device Reference 510(k) Number(s)": [],
    "Regulatory Class": "Class III",
    "Product Code(s)": [
        "MOB"
    ],
    "Summary Letter Date": "May 25, 2010",
    "Summary Letter Received Date": "June 1, 2010",
    "Submission Date": "",
    "Regulation Number(s)": [
        "21 CFR 866.5660"
    ],
    "Regulation Name(s)": [
        "Multiple autoantibodies immunological test system"
    ],
    "Analyte Class(es)": [
        "autoimmune",
        "immunology"
    ],
    "Analyte(s)": [
        "Antibodies against proteinase 3 (PR3)"
    ],
    "Specimen Type(s)": [
        "Serum"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [],
    "Method(s)/Technology(ies)": [
        "Enzyme immunoassay (EIA)"
    ],
    "Methodologies": [
        "Solid phase enzyme immunoassay"
    ],
    "Submission Type(s)": [
        "Assay"
    ],
    "Document Summary": "FDA 510(k) summary for AESKULISA PR3 enzyme immunoassay for detection of anti-PR3 antibodies in human serum",
    "Indications for Use Summary": "Aid in diagnosis of Wegener's granulomatosis by semiquantitative and qualitative detection of antibodies against proteinase 3 in human serum, to be used alongside other serological tests and clinical findings",
    "fda_folder": "Immunology"
}